Hong Kong Stock Movement
DIAGENS-B rose 18.59%. Based on recent key news:
<ol>
<li>
On March 30, DIAGENS-B was listed on the Hong Kong Stock Exchange for the first time, with an opening price up 121.2% from the issue price, showing strong market interest in its medical imaging large model platform. This platform breaks through the limitations of traditional medical imaging AI, covering various medical imaging modalities, driving a significant increase in stock price. Source: Zhitong Finance
</li>
<li>
On March 30, DIAGENS-B received 1,073 times subscription during the public offering phase, demonstrating high investor attention and market enthusiasm, further pushing up the stock price. Source: Guandian Network
</li>
<li>
On March 30, DIAGENS-B's stock price performed strongly in dark trading, with a maximum increase of over 110%, reflecting optimistic market expectations for its future growth potential. Source: DoNews The Hong Kong stock market's funds are concentrated in AI and other hard technology sectors.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Kangfang Biotech rose 6.45%. Based on recent key news:
<ol>
<li>
On March 30, Kangfang Biotech's two globally innovative tumor immunotherapy dual-antibody drugs were included in the national medical insurance catalog for the first time, driving up the stock price. The company's revenue is expected to grow by 43.9% year-on-year to RMB 3.056 billion in 2025, showing strong market performance.
</li>
<li>
On March 30, Kangfang Biotech was rated as one of the highest speculative value securities for short-term trading, attracting investor attention. Its performance in the healthcare industry is particularly outstanding, further pushing up the stock price.
</li>
<li>
On April 1, Kangfang Biotech's Yivofex's listing application has been accepted by the U.S. FDA, with a decision expected in November. This news has strengthened market confidence in its future growth, boosting the stock price. The healthcare industry is performing strongly, with significant capital inflow.
</li>
</ol>
Sanofi Biotech rose 10.95%. Based on recent key news:
<ol>
<li>
On April 1, Sanofi Biotech announced a physical distribution of Mandi International shares, with the stock price opening high and rising significantly. This move is seen as a direct return to shareholders, pushing the stock price up by 10.25%. Source: Zhitong Finance
</li>
<li>
On March 30, Sanofi Biotech announced its 2025 performance, with significant increases in revenue and net profit. Revenue increased by 94.3%, and net profit grew by 305.8%, showing the company's strong financial performance and boosting market confidence. Source: Zhitong Finance
</li>
<li>
On March 31, biomedicine was listed as a new emerging pillar industry in the country, and policy support has enhanced market confidence in Sanofi Biotech. The company's potential in innovative drug research and development has gained international recognition, further driving up the stock price. Source: Zhitong Finance Policy support for the biomedicine industry has strengthened, and market confidence has improved.
</li>
</ol>
Innovent Biologics rose 6.30%. Based on recent key news:
<ol>
<li>
On March 31, Innovent Biologics announced its fiscal year 2025 performance, recording a net profit of RMB 834 million for the first time, with total revenue reaching RMB 13 billion, a year-on-year increase of 38%. This strong performance has boosted market confidence, driving up the stock price. Source: Jinshi Data
</li>
<li>
On March 30, Innovent Biologics' MaShidu peptide achieved its primary endpoint in Phase Ib clinical studies among the adolescent obesity population in China, demonstrating superior efficacy in weight loss and blood sugar reduction. This breakthrough has enhanced investors' expectations for the company's future growth. Source: Time Online
</li>
<li>
On March 30, Innovent Biologics announced the granting of stock options and restricted shares to grantees, reflecting the company's confidence in future development and further boosting market sentiment. Source: Zhitong Finance The innovative drug industry faces pressure from medical insurance and internationalization challenges.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
BeiGene rose by 7.46%. Based on recent key news:
<ol>
<li>
On March 30, the National Medical Products Administration announced that the total amount of innovative drug licensing transactions exceeded USD 60 billion, with BeiGene participating in multiple transactions, driving up the stock price. Industrial Securities pointed out that China's innovative drugs continue to strengthen their global competitiveness, and the industrial logic of commercialized profitability remains unchanged.
</li>
<li>
On April 1, BeiGene recorded large transactions in pre-market trading, with a transaction price 0.84% higher than the previous closing price, and a transaction amount of HKD 75.2394 million, indicating positive market sentiment towards its stock.
</li>
<li>
On March 30, the biopharmaceutical industry was positioned as an important pillar for economic growth and industrial upgrading, with innovative drugs as a high value-added segment, clear development direction, further enhancing market confidence in BeiGene. The innovative drug sector has significant development potential, with noticeable capital inflows
</li>
</ol>

02526

DIAGENS-B rose 18.59%; CanSino Biologics rose 6.45%, with a transaction volume of HKD 1.269 billion; 3SBio rose 10.95%, with a transaction volume of HKD 1.143 billion; Innovent Biologics rose 6.30%, with a transaction volume of HKD 1.136 billion; BeiGene rose 7.46%, with a market capitalization of HKD 284.2 billion

HK Stock Movers Tracker

DIAGENS-B

Hong Kong Stock Movement: DIAGENS-B surged 18.59% on its first day of listing, with high subscription rates and strong dark pool trading igniting market enthusiasm